Maraviroc: all 119 studies that test it
Page 1 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Anti-inflammation Treatment for Idiopathic Inflammatory MyopathiesNot yet recruitingNCT07668505Phase 4
- Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After StrokeRecruitingNCT07080567Phase 2
- A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVIDNot yet recruitingNCT06974084Phase 2/3
- This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft DysfunctionRecruitingNCT06853223Phase 2
- Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsRecruitingNCT06805656Phase 2
- Antiviral Clinical Trial for Long Covid-19RecruitingNCT06511063Phase 2
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...RecruitingNCT05470491Phase 1/2
- The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After StrokeRecruitingNCT04789616Phase 2
- Maraviroc in Patients With Moderate and Severe COVID-19CompletedNCT04435522Phase 1Results posted
- Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRCCompletedNCT03274804Phase 1Results posted
- ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-AdherenceCompletedNCT03218592Phase 4Results posted
- Maraviroc to Augment Rehabilitation Outcomes After StrokeTerminatedNCT03172026Phase 2/3Results posted
- Maraviroc Efficacy for Hepatitis CCompletedNCT02881762Phase 4Results posted
- Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 InfectionCompletedNCT02778204Phase 1Results posted
- Impact of CCR5 Blockade in HIV+ Kidney Transplant RecipientsCompletedNCT02741323Phase 2Results posted
- THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROCCompletedNCT02625207Phase 1Results posted
- Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)CompletedNCT02519777Phase 4Results posted
- Characterization and Modulation of Mucosal Immunity for HIV Prevention in WomenTerminatedNCT02333045Not applicableResults posted
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
- Maraviroc as GVHD Prophylaxis in Transplant RecipientsTerminatedNCT02167451Phase 1/2Results posted
- Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis ImmunophenotypesTerminatedNCT02134717Not applicableResults posted
- A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of MaravirocCompletedNCT01894776Phase 1Results posted
- Phase II Maraviroc for GVHD PreventionCompletedNCT01785810Phase 2Results posted
- Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenCompletedNCT01505114Phase 2Results posted
- A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)CompletedNCT01449006Phase 4Results posted
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedNCT01400412Phase 2Results posted
- The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic StudyCompletedNCT01348763Phase 1Results posted
- Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1TerminatedNCT01345630Phase 3Results posted
- A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis BCompletedNCT01327547Phase 4Results posted
- Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)CompletedNCT01276236Phase 2Results posted
- R5 Integrase Study in HIV-1 Naive PatientsCompletedNCT01204905Not applicableResults posted
- Effects of Intensive cART During Acute/Early HIV InfectionCompletedNCT01154673Phase 2/3Results posted
- Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)TerminatedNCT01068873Phase 4Results posted
- Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1CompletedNCT00993148Phase 2Results posted
- Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA LevelsCompletedNCT00987948Phase 2Results posted
- The Maraviroc Central Nervous System (CNS) StudyCompletedNCT00982878Phase 1Results posted
- Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell TransplantationCompletedNCT00948753Phase 1/2Results posted
- CCR5 Inhibitor Treatment Intensification on CD4+ T-cell RecoveryCompletedNCT00925756Phase 4Results posted
- A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc TherapyCompletedNCT00870363Phase 4Results posted
- Effect of Maraviroc on Endothelial Function in HIV-Infected PatientsCompletedNCT00844519Phase 3Results posted
- A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected PatientsCompletedNCT00827112Phase 2Results posted
- An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic ChildrenStatus unknownNCT00791700Phase 2Results posted
- An Interaction Study to Assess Drug Levels in Healthy Adult SubjectsCompletedNCT00764465Phase 2Results posted
- Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic FailureCompletedNCT00735072Phase 4Results posted
- Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic SuppressionCompletedNCT00709111Not applicableResults posted
- A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy SubjectsCompletedNCT00666705Phase 4Results posted
- Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedNCT00537394Phase 3Results posted
- Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)CompletedNCT00525733Not applicableResults posted
- Multicenter Pilot Study To Define The Marker As An Alternate For Tropism AssayTerminatedNCT00496782Phase 1Results posted
- Multicenter, Safety Study Of MaravirocCompletedNCT00478231Phase 3Results posted
- Maraviroc in Rheumatoid ArthritisTerminatedNCT00427934Phase 2Results posted
- Expanded Access Program for Maraviroc At Multiple CentersCompletedNCT00426660Phase 3Results posted
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected SubjectsCompletedNCT00098748Phase 2/3Results posted
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsCompletedNCT00098722Phase 2/3Results posted
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsCompletedNCT00098306Phase 2/3Results posted
- Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/LamivudineCompletedNCT00098293Phase 3Results posted
- Safety of Maraviroc for Post-stroke DepressionCompletedNCT05932550Phase 2
- Safety and Efficacy of Maraviroc in Post-stroke Cognitive ImpairmentStatus unknownNCT04966429Phase 2
- The Role of Home Packs of HIV PEPSE in High Risk IndividualsCompletedNCT04965662Phase 4
- Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedNCT04721301Phase 1
- Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).TerminatedNCT04441385Phase 2
- Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected PatientsWithdrawnNCT03708861Phase 3
- Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.CompletedNCT03402815Phase 4
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 RatioCompletedNCT03178084Phase 3
- Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)TerminatedNCT03163277Phase 4
- Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIVCompletedNCT03129113Phase 2/3
- Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant RecipientsWithdrawnNCT02990312Phase 4
- Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing CureCompletedNCT02961829Not applicable
- Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected PatientsCompletedNCT02934022Not applicable
- Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related TransplantationStatus unknownNCT02799888Phase 2
- Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 EradicationTerminatedNCT02486510Early Phase 1
- A Open-label, Drug-Drug Interaction With Maraviroc (DDI)CompletedNCT02480894Phase 1
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedNCT02475915Phase 1/2
- Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative AdultsCompletedNCT02346084Phase 1
- Maraviroc and NeuroAIDS PathogenesisCompletedNCT02159027Phase 2/3
- A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal ExplantsCompletedNCT02039323Phase 1
- Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its MetabolitesCompletedNCT01980329Phase 1
- Switching Undetectables to SelzentryCompletedNCT01866267Phase 4
- Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in WomenCompletedNCT01749566Phase 1
- First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy VolunteersCompletedNCT01719627Phase 1
- A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON StudyCompletedNCT01680536Phase 4
- MARCH Renal SubstudyCompletedNCT01637259Phase 4
- The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy VolunteersCompletedNCT01627717Phase 1
- Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy SubjectsCompletedNCT01597895Phase 1
- A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™CompletedNCT01597648Phase 1
- Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)CompletedNCT01533272Phase 4
- Maraviroc Abacavir STudy - Effect on Endothelial RecoveryStatus unknownNCT01389063Phase 4
- Maraviroc Switch Collaborative StudyCompletedNCT01384682Phase 4
- Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected PatientsCompletedNCT01348308Phase 3
- Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 PatientsStatus unknownNCT01291459Phase 2
- Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy SubjectsCompletedNCT01290211Phase 1
- A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in BelgiumWithdrawnNCT01242579Phase 1
- Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3Status unknownNCT01235013Phase 4
- PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing RegimenCompletedNCT01190293Phase 4
- Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy SubjectsTerminatedNCT01140412Phase 1
- Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)CompletedNCT01133210Phase 1
- Effect Of Maraviroc On The Pharmacokinetics Of DigoxinCompletedNCT01056874Phase 1
- Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel AntigensTerminatedNCT01049204Phase 4
- Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
- Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected PatientsStatus unknownNCT01013987Phase 4